Ann E Almazar1, Nicholas J Talley1,2, Joseph J Larson3, Elizabeth J Atkinson3, Joseph A Murray1,4, Yuri A Saito1. 1. Department of Medicine, Division of Gastroenterology and Hepatology. 2. Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia. 3. Department of Health, Division of Biomedical Statistics and Informatics. 4. Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
BACKGROUND AND AIMS: Routine serologic testing for celiac disease (CD) may be useful in irritable bowel syndrome (IBS) patients, but this is controversial. We aimed to compare the prevalence of unrecognized CD in a large cohort of patients with and without IBS. PARTICIPANTS AND METHODS: This is a family case-control IBS study conducted at a single US academic medical center. Stored serum and DNA were available. Tissue transglutaminase (TTg) immunoglobulin A was performed, followed by indirect immunofluorescence testing for endomysial antibodies with positive or weakly positive TTg results. Individuals were considered to have CD if both results were positive. χ and Fisher's exact tests were used to compare prevalence between the two groups. RESULTS: Serum samples were studied from 533 cases and 531 controls. In all, 80% of participants were female, with a median age of 50 years; 65% of cases and 0% controls met the Rome criteria for IBS. Previous serological testing for CD had occurred in 142 (27%) cases and 13 (2%) controls, but none had CD on subsequent testing. Six (1.1%) cases versus five (0.9%) controls had positive or weakly positive TTg test. Six cases (1.1%) versus three (0.6%) controls were confirmed to have CD by endomysial antibody (P=0.51). CONCLUSION: No difference in the prevalence of CD between patients with IBS and patients without IBS at a tertiary medical center was observed. Our findings do not support routine celiac serologic or genetic testing in patients with IBS in all US populations.
BACKGROUND AND AIMS: Routine serologic testing for celiac disease (CD) may be useful in irritable bowel syndrome (IBS) patients, but this is controversial. We aimed to compare the prevalence of unrecognized CD in a large cohort of patients with and without IBS. PARTICIPANTS AND METHODS: This is a family case-control IBS study conducted at a single US academic medical center. Stored serum and DNA were available. Tissue transglutaminase (TTg) immunoglobulin A was performed, followed by indirect immunofluorescence testing for endomysial antibodies with positive or weakly positive TTg results. Individuals were considered to have CD if both results were positive. χ and Fisher's exact tests were used to compare prevalence between the two groups. RESULTS: Serum samples were studied from 533 cases and 531 controls. In all, 80% of participants were female, with a median age of 50 years; 65% of cases and 0% controls met the Rome criteria for IBS. Previous serological testing for CD had occurred in 142 (27%) cases and 13 (2%) controls, but none had CD on subsequent testing. Six (1.1%) cases versus five (0.9%) controls had positive or weakly positive TTg test. Six cases (1.1%) versus three (0.6%) controls were confirmed to have CD by endomysial antibody (P=0.51). CONCLUSION: No difference in the prevalence of CD between patients with IBS and patients without IBS at a tertiary medical center was observed. Our findings do not support routine celiac serologic or genetic testing in patients with IBS in all US populations.
Authors: Tobias G Wenzl; Marc A Benninga; Clara M Loots; Silvia Salvatore; Yvan Vandenplas Journal: J Pediatr Gastroenterol Nutr Date: 2012-08 Impact factor: 2.839
Authors: Brooks D Cash; Joel H Rubenstein; Patrick E Young; Andrew Gentry; Borko Nojkov; Dong Lee; A Hirsohi Andrews; Richard Dobhan; William D Chey Journal: Gastroenterology Date: 2011-07-14 Impact factor: 22.682
Authors: Kent D Katz; Shahrooz Rashtak; Brian D Lahr; L Joseph Melton; Patricia K Krause; Kristine Maggi; Nicholas J Talley; Joseph A Murray Journal: Am J Gastroenterol Date: 2011-03-01 Impact factor: 10.864
Authors: T P Chorzelski; E H Beutner; J Sulej; H Tchorzewska; S Jablonska; V Kumar; A Kapuscinska Journal: Br J Dermatol Date: 1984-10 Impact factor: 9.302
Authors: G Richard Locke; Joseph A Murray; Alan R Zinsmeister; L Joseph Melton; Nicholas J Talley Journal: Mayo Clin Proc Date: 2004-04 Impact factor: 7.616
Authors: David S Sanders; Dina Patel; Timothy J Stephenson; Anthony Milford Ward; Eugene V McCloskey; Marios Hadjivassiliou; Alan J Lobo Journal: Eur J Gastroenterol Hepatol Date: 2003-04 Impact factor: 2.566